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ABSTRACT 

PRE CLINICAL TRIAL AUTOLOGUS MSC BONE MARROW STEM CELL AND 

ALLOGENIC PANCREATIC STEM CELL FOR REPAIR OF BETA PANCREATIC 

CELL IN DIABETES MELLITUS WISTAR 

Background: Diabetes Mellitus (DM) is a group of metabolic diseases due to abnormal 
insulin secretion, insulin action or both. This pancreatic produced insulin has an important 
function in the body in glucose regulation and utilization in almost all body tissues, especially 
muscle, fat and liver. When there are disorders of insulin secretion and utilization that results 
in diabetes mellitus, alternative therapies in DM management is the use of stem cells. Stem 
cell therapy alternative used here used the cells taken from adult stem cell, the bone marrov. 
stem cell, and from transplanted pancreatic cells from donor. 
Methods: This was a trial used animal models of DM induced Wistar with 50 mglkg Aloxan. 
DM Wistars were divided into 4 treatment groups, group 1 was transplanted with autologous 
MSCs bone marrow stem cell, group 2 was given allogenic pancreatic stem cells injected 
with open laparotomy and intra peritoneal, group 3 was given with insulin subcutaneously, 
and group 4 served as control. MSC was characterized by DAB immunostaining using CD44 
and CD 105 markers,· whereas pancreatic cell characterization was done by 
immunofluoresence with nestin marker as well as Elisa c peptide and insulin. The dosage was 
200,000 cells/rats. The results were evaluated for BSN blood sugar, 2 hours PP, C peptide, 
and insulin. The results were analyzed with T test. 
Results: Post therapy results in group 1 revealed significant decrease of blood sugar levels, 
both BSN and 2-hour PP (p = 0015), an increase in insulin levels (p = 0015) and increased 
insulin levels (p = 0.002). In group 2, there was decreased levels of BSN and 2-hour PP 
(0.002), an increase in insulin levels (p = 0.000), and increased level of C peptide (p = 0.003). 
Those receiving insulin also showed decreased levels of blood sugar, although the decrease 
was not as good as that in those receiving MSC and pancreatic (p = 0.002), increased insulin 
levels (p = 0.001) and increased levels of C peptide (p = 0088). Control group did not show 
decreased levels of sugar. Reduction in BSN level, 2 hours PP, increased c peptide and 
insulin in pancreatic stem cell administration was significant as compared to the MSC and 
insulin. 
Conclusion: The administration of pancreatic stem cell therapy produces the best outcome 
among MSC and insulin in DM wistar. 
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